Safety and efficacy of a defined bacterial consortium, VE303, to treat HE
Open Access
- 19 February 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (3)
Abstract
Background: Novel therapies are needed to treat HE, and microbiome modulation is a promising target. VE303 is a defined consortium of 8 purified, clonal bacterial strains, known to produce metabolites that may be beneficial in HE. We evaluated the safety and efficacy of VE303 to treat HE. Methods: We performed a single-center, randomized, placebo-controlled trial of VE303 in adult patients with a history of overt HE (NCT04899115). Eligible patients were taking lactulose and rifaximin, had no recent systemic antibiotics, and had MELD ≤20. All patients received 5 days of oral vancomycin followed by randomization to 14 days of VE303 or placebo (2:1). The primary endpoints were incidence of serious adverse events and change in psychometric HE score (PHES) from baseline to 4 weeks after treatment. Stool samples underwent metagenomic sequencing and metabolite quantification. Results: Eighteen patients completed the trial, 56% men, with a mean age of 59 years and a mean MELD of 11. Patients who received VE303 had a mean change in PHES of +1.5 versus −1.0 in those who received a placebo (p=0.20). Two of the 12 patients who received VE303 had at least 1 serious adverse event (all overt HE hospitalizations), compared with 0/6 patients who received a placebo. In the patients who received VE303, 2 of 8 strains engrafted in >50% of patients. Both VE303 strain engraftment and increased stool butyrate production had a trend toward improved PHES. Conclusions: VE303 was well tolerated in patients with cirrhosis and a history of overt HE, leading to the engraftment of certain VE303 strains and a higher percentage of patients with improved PHES.Keywords
This publication has 31 references indexed in Scilit:
- Bile Acids in Hepatic EncephalopathyJournal of Clinical and Experimental Hepatology, 2019
- Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ FailuresClinical Gastroenterology and Hepatology, 2017
- Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota CompositionClinical and Translational Gastroenterology, 2016
- Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of HospitalizationAmerican Journal of Gastroenterology, 2014
- Altered profile of human gut microbiome is associated with cirrhosis and its complicationsJournal of Hepatology, 2014
- Trimmomatic: a flexible trimmer for Illumina sequence dataBioinformatics, 2014
- Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier functionJournal of Hepatology, 2013
- Metagenomic biomarker discovery and explanationGenome Biology, 2011
- Rifaximin Treatment in Hepatic EncephalopathyNew England Journal of Medicine, 2010
- Bacterial translocation of enteric organisms in patients with cirrhosisJournal of Hepatology, 2001